EGFR and neoplasm: MCLA-158 showed antitumor activity against RAS mutated and wt CRC patient-derived organoids in vitro and induced either tumor regression or stasis in esophageal squamous and gastric adenocarcinoma patient-derived xenograft models expressing LGR5 and EGFR (166).